2-(1H-indazol-3-ylamino)-N-(4-piperazin-1-ylpyridin-3-yl)-1,3-thiazole-4-carboxamide | 1023654-87-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 2-(1H-indazol-3-ylamino)-N-(4-piperazin-1-ylpyridin-3-yl)-1,3-thiazole-4-carboxamide
• CAS: 1023654-87-6
• 化学式: C₂₀H₂₀N₈OS
• 分子量: 420.498
• InChiKey: NJMCPVDHDBTTBG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  139
• 氢给体数：
  4
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  tert-butyl 4-(3-(2-((1H-indazol-3-yl)amino)thiazole-4-carboxamido)pyridin-4-yl)piperazine-1-carboxylate 在 三氟乙酸 作用下， 以 neat (no solvent) 为溶剂， 反应 0.25h， 生成 2-(1H-indazol-3-ylamino)-N-(4-piperazin-1-ylpyridin-3-yl)-1,3-thiazole-4-carboxamide
  参考文献：
  名称：

  Structure-based design and optimization of 2-aminothiazole-4-carboxamide as a new class of CHK1 inhibitors

  摘要：

  Drug design efforts in the emerging 2-aminothiazole-4-carboxamide class of CHK1 inhibitors have uncovered specific combinations of key substructures within the molecule; resulting in significant improvements in cell-based activity while retaining a greater than one hundred-fold selectivity against CDK2. The X-ray crystal structure of a complex between compound 39 and the CHK1 protein detailing a 'U-shaped' topology and key interactions with the protein surface at the ATP site is also reported. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.02.108

文献信息

• 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP2078002B1

  公开（公告）日：2013-08-28
• US8227605B2
  申请人：——

  公开号：US8227605B2

  公开（公告）日：2012-07-24
• [EN] 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS<br/>[FR] AMIDES 2-AMINOTHIAZOLE-4-CARBOXYLIQUES UTILISÉS COMME INHIBITEURS DE PROTÉINES KINASES
  申请人：SCHERING CORP

  公开号：WO2008054701A1

  公开（公告）日：2008-05-08

  [EN] The present invention relates to novel Anilinopiperazine Derivatives of formula (I), compositions comprising the Anilinopiperazine Derivatives, and methods for using the Anilinopiperazine Derivatives for treating or preventing a proliferative disorder, an anti-proliferative disorder, inflammation, arthritis, a central nervous system disorder, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral disease, a fungal infection, or a disorder related to the activity of a protein kinase.
  [FR] La présente invention concerne de nouveaux dérivés d'anilinopipérazine de formule (I), des compositions comprenant ces dérivés d'anilinopipérazine ainsi que des méthodes d'utilisation de ces dérivés d'anilinopipérazine pour traiter ou prévenir un trouble prolifératif, un trouble anti-prolifératif, l'inflammation, l'arthrite, un trouble du système nerveux central, une maladie cardiovasculaire, l'alopécie, une maladie neuronale, une lésion ischémique, une maladie virale, une infection fongique ou un trouble associé à l'activité d'une protéine kinase.
• Structure-based design and optimization of 2-aminothiazole-4-carboxamide as a new class of CHK1 inhibitors
  作者：Xiaohua Huang、Cliff C. Cheng、Thierry O. Fischmann、José S. Duca、Matthew Richards、Praveen K. Tadikonda、Panduranga Adulla Reddy、Lianyun Zhao、M. Arshad Siddiqui、David Parry、Nicole Davis、Wolfgang Seghezzi、Derek Wiswell、Gerald W. Shipps

  DOI：10.1016/j.bmcl.2013.02.108

  日期：2013.5

  Drug design efforts in the emerging 2-aminothiazole-4-carboxamide class of CHK1 inhibitors have uncovered specific combinations of key substructures within the molecule; resulting in significant improvements in cell-based activity while retaining a greater than one hundred-fold selectivity against CDK2. The X-ray crystal structure of a complex between compound 39 and the CHK1 protein detailing a 'U-shaped' topology and key interactions with the protein surface at the ATP site is also reported. (C) 2013 Elsevier Ltd. All rights reserved.